Kemper (NYSE:KMPR) Upgraded to Buy at StockNews.com
by Tristan Rich · The Markets DailyKemper (NYSE:KMPR – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Monday.
Several other research firms have also recently weighed in on KMPR. Raymond James boosted their price objective on shares of Kemper from $70.00 to $75.00 and gave the stock a “strong-buy” rating in a research report on Thursday, August 8th. JMP Securities reaffirmed a “market outperform” rating and set a $85.00 price target on shares of Kemper in a research note on Tuesday, October 15th. UBS Group boosted their price target on shares of Kemper from $67.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. Finally, Piper Sandler raised their price objective on shares of Kemper from $77.00 to $80.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $76.20.
Check Out Our Latest Report on Kemper
Kemper Price Performance
KMPR traded up $0.19 during midday trading on Monday, reaching $62.62. 516,046 shares of the company’s stock were exchanged, compared to its average volume of 375,700. Kemper has a one year low of $38.52 and a one year high of $67.60. The firm has a market capitalization of $4.01 billion, a price-to-earnings ratio of 14.91 and a beta of 0.85. The business has a 50-day simple moving average of $61.62 and a two-hundred day simple moving average of $60.68. The company has a quick ratio of 0.22, a current ratio of 0.22 and a debt-to-equity ratio of 0.50.
Kemper (NYSE:KMPR – Get Free Report) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.28. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.07 billion. Kemper had a net margin of 5.86% and a return on equity of 12.03%. The firm’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.44) EPS. As a group, research analysts predict that Kemper will post 5.06 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its position in shares of Kemper by 114.7% during the 3rd quarter. GAMMA Investing LLC now owns 541 shares of the insurance provider’s stock worth $33,000 after purchasing an additional 289 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Kemper by 5,590.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 569 shares of the insurance provider’s stock valued at $35,000 after buying an additional 559 shares in the last quarter. LRI Investments LLC acquired a new position in Kemper during the first quarter worth $36,000. Quarry LP raised its position in Kemper by 105.1% during the second quarter. Quarry LP now owns 642 shares of the insurance provider’s stock worth $38,000 after acquiring an additional 329 shares in the last quarter. Finally, Capital Performance Advisors LLP acquired a new stake in Kemper in the third quarter valued at $46,000. Institutional investors own 86.23% of the company’s stock.
About Kemper
Kemper Corporation, a diversified insurance holding company, engages in the provision of insurance products to individuals and businesses in the United States. The company operates through three segments: Specialty Property & Casualty Insurance, Preferred Property & Casualty Insurance, and Life & Health Insurance.
Read More
- Five stocks we like better than Kemper
- 3 Stocks to Consider Buying in October
- Intel: Is Now the Time to Be Brave?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Using the MarketBeat Stock Split Calculator
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?